Company profile: Wilson Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical R&D focused on rare diseases, developing Decuprate as a new treatment for Wilson Disease, currently in a Phase II clinical study; based in Stockholm, Sweden.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Wilson Therapeutics
Vtesse Pharma
HQ: United States
Website
- Description: Provider of rare disease drug development for underserved patients, working collaboratively to advance VTS-270, which has shown promise in pre-clinical and clinical studies as a potential treatment for Niemann-Pick Disease; first spin-out of Cydan Development, Inc., an orphan-drug accelerator.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vtesse Pharma company profile →
Lumena Pharma
HQ: United States
Website
- Description: Provider of oral therapeutics for rare liver diseases, with clinical-stage candidates that selectively target a transporter in the intestine to improve liver function and relieve symptoms. Offers GMP-compliant nutraceutical manufacturing (capsules, tablets, powders, coatings), laboratory/testing and consulting, private label solutions, quality assurance, and plans distribution of generic pharmaceutical brands.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumena Pharma company profile →
Eidos Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology research and development of novel, genetically targeted therapies to improve the lives of patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eidos Therapeutics company profile →
Lung Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceutical therapies targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Pipeline includes LTI-03, a dual-mechanism dry powder inhaled treatment for idiopathic pulmonary fibrosis to improve lung function and reduce side effects, and LTI-01, a therapy for loculated pleural effusion that breaks down fibrous tissue to promote fluid drainage and alleviate symptoms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lung Therapeutics company profile →
Spexis
HQ: Switzerland
Website
- Description: Provider of macrocycle drug discovery and development addressing high unmet medical needs, offering ColiFin (EU-approved inhaled therapy for chronic infections in cystic fibrosis, seeking U.S. approval); inhaled murepavadin for Pseudomonas aeruginosa infections; balixafortide, a macrocyclic CXCR4 inhibitor; and Macrocycle and OMPTA platforms for rare diseases and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spexis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Wilson Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Wilson Therapeutics
2.2 - Growth funds investing in similar companies to Wilson Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Wilson Therapeutics
4.2 - Public trading comparable groups for Wilson Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →